Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-105180
Filing Date
2024-09-10
Accepted
2024-09-10 16:38:15
Documents
84
Period of Report
2024-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q engn-20240731.htm   iXBRL 10-Q 2248445
2 EX-10.3 engn-ex10_3.htm EX-10.3 141380
3 EX-10.4 engn-ex10_4.htm EX-10.4 86212
4 EX-10.5 engn-ex10_5.htm EX-10.5 64992
5 EX-31.1 engn-ex31_1.htm EX-31.1 19552
6 EX-31.2 engn-ex31_2.htm EX-31.2 19113
7 EX-32.1 engn-ex32_1.htm EX-32.1 9788
8 EX-32.2 engn-ex32_2.htm EX-32.2 9791
  Complete submission text file 0000950170-24-105180.txt   10519637

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20240731.xsd EX-101.SCH 1781820
87 EXTRACTED XBRL INSTANCE DOCUMENT engn-20240731_htm.xml XML 1528209
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-41854 | Film No.: 241290520
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)